Previous 10 | Next 10 |
The following slide deck was published by Codexis, Inc. in conjunction with this Read more ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Retailers cap off the Q1 earnings season in style as Target (TGT), Best Buy (BBY), ...
REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces the signing of a CodeEvolver ® platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license to its p...
REDWOOD CITY, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in three upcoming investment conferences: UBS Global Healthcare Conference on May 21 at 8:00 a.m. Eastern time at the ...
Codexis, Inc. (CDXS) Q1 2019 Earnings Conference Call May 06, 2019, 04:30 PM ET Company Participants Jody Cain - LHA John Nicols - President and CEO Gordon Sangster - SVP and Chief Financial Officer Conference Call Participants Brandon Couillard - Jefferies Matthew Hewitt...
Codexis (NASDAQ: CDXS ): Q1 Non-GAAP EPS of -$0.05 beats by $0.03 ; GAAP EPS of -$0.09. More news on: Codexis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Total revenues increase 11% to $15.6 million, product revenue up 30% Recent highlights include Third CodeEvolver ® Platform Technology Agreement and Multi-Year Enzyme Supply and Licensing Agreement with Tate & Lyle for TASTEVA ® M Stevia Sweetener Conference call be...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 102 weeks of public selections as part of this ongoing live forward-testing. In...
REDWOOD CITY, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a multi - year agreement with Tate & Lyle, a global provider of food ingredients and solutions, for the supply and licensing of novel Co...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...